Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings Plc, a developer of novel immunotherapies for cancer treatment, has announced its Annual General Meeting (AGM) to be held on October 25, 2024, in London, where the senior management will present the final results for the fiscal year and conduct a Q&A session. Shareholders are invited to attend the event which follows the release of the company’s Annual Report and Accounts, now available on their website. Scancell is known for its innovative product pipeline, utilizing its proprietary technology platforms to address unmet needs in cancer treatment.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
